A pioneering investigation led by researchers at the University of California San Diego School of Medicine has unveiled the potential of ketogenic therapy as a transformative treatment approach for adults suffering from anorexia nervosa, specifically those with weight-normalized or mildly underweight conditions. Published in the prestigious journal Communications Medicine, this pilot trial explores the feasibility, safety, and clinical efficacy of a stringent ketogenic diet characterized by a high-fat, adequately moderate-protein, and low-carbohydrate composition. The study breaks new ground by focusing on metabolic regulation as a cornerstone for ameliorating the entrenched psychological and physiological symptoms prevalent in this notoriously difficult-to-treat psychiatric disorder.
Anorexia nervosa remains a critical public health challenge marked by one of the highest mortality rates among psychiatric illnesses worldwide. Conventional treatments have predominantly concentrated on behavioral and cognitive interventions targeted at symptom management and weight restoration, yet relapse rates remain alarmingly high. Even after achieving weight normalization, many patients struggle with pervasive body image distortions, intense food-related anxieties, and other psychological disturbances, underscoring the imperative for innovative therapeutic paradigms that address the underlying neurobiological dysfunctions.
The impetus for this groundbreaking research stems from an emerging body of evidence implicating neurometabolic irregularities in the pathophysiology of anorexia nervosa. Dr. Guido Frank, the principal investigator and psychiatry professor with over 25 years of clinical experience in eating disorder management, hypothesizes that these metabolic abnormalities could critically impair neural circuits governing appetite, mood regulation, and cognitive control. This pilot clinical study attempts to address such disruptions by leveraging the ketogenic diet’s capacity to recalibrate brain metabolism, an approach previously validated in epilepsy and other neurological conditions.
Over a carefully supervised 14-week outpatient clinical protocol, twenty-two adults diagnosed with weight-normalized or mildly underweight anorexia nervosa were administered a stringent ketogenic nutritional regimen. The study demonstrated a high retention rate, with 82% completing the full intervention without adverse events or significant weight loss, thereby establishing the intervention’s safety and tolerability. Importantly, the lack of further BMI reduction signals the diet’s appropriateness in this delicate cohort where weight maintenance is critical, challenging prior apprehensions regarding restrictive dietary therapies.
Symptomatically, the results were remarkable. Approximately 72% of those completing the trial achieved scores in the recovered range across standardized eating disorder assessments like the Eating Disorder Examination Questionnaire (EDE-Q) and Eating Disorder Inventory-3 (EDI-3). Concurrently, all participants exhibited marked reductions in depressive symptomatology as quantified by the Beck Depression Inventory (BDI), with 72% attaining normal-range depression scores by the end of the intervention. These improvements suggest not only metabolic stabilization but also significant psychological relief, providing compelling clinical evidence that targeting brain metabolism can ameliorate both physical and mental health aspects of anorexia nervosa.
This study is particularly notable for its methodological rigor amidst the fraught clinical sensitivity surrounding dietary interventions in this vulnerable population. The ketogenic diet, often dismissed due to fears of exacerbating restrictive pathology, was implemented under stringent medical supervision and comprehensive psychoeducation, allowing participants to maintain high adherence rates. This critical support framework mitigated risks typically associated with nutritional interventions in eating disorders, such as rapid weight loss or nutritional deficiencies, underscoring the necessity of specialized care modalities when deploying metabolic therapies.
The genesis of this research also carries a profoundly human element, shared by co-author Dr. Barbara Scolnick, an internal medicine specialist who was inspired by her niece’s decade-long battle with anorexia nervosa. Traditional treatments had failed to achieve remission, but the introduction of ketogenic therapy in combination with other therapeutic modalities catalyzed a remarkable path to recovery. Her personal account further legitimizes the scientific hypotheses and exemplifies how metabolic interventions could revolutionize the treatment landscape for eating disorders.
While cautious in their conclusions, the authors stress that the findings present critical proof of concept, building on prior smaller-scale and preclinical studies that link metabolic dysregulation to anorexia nervosa pathology. This pilot trial offers a new therapeutic avenue by shifting the paradigm from solely psychotherapeutic strategies to integrating metabolic correction, potentially addressing the persistent neurobiological substrates underlying symptom chronicity and relapse risk. Such innovative approaches could ultimately transform clinical care standards by introducing targeted nutritional psychiatry into multidisciplinary treatment frameworks.
The significance of this study extends beyond anecdotal success; it invites a paradigm shift in how researchers and clinicians conceptualize and approach mental health disorders with a metabolic underpinning. Dr. Jan Ellison Baszucki, co-founder and president of the study’s fundraising entity, Baszucki Group, underscores the broader implications for neuropsychiatric research, emphasizing ketogenic therapy’s promise in normalizing brain function in even the most intractable conditions. This venture also highlights the critical role of philanthropy in supporting high-risk, high-reward scientific innovations that could redefine treatment paths.
Future directions are already taking shape, with an ongoing extension trial recruiting participants diagnosed with both anorexia nervosa and bulimia nervosa. The nationwide study aims to further validate the efficacy of ketogenic therapy across diverse eating disorder diagnoses and inform larger-scale randomized controlled trials. This progression exemplifies the translational science model, rapidly moving from promising pilot data to expansive clinical applications that could potentially reshape the therapeutic landscape of eating disorders.
In sum, this seminal pilot trial reveals ketogenic therapy as a feasible, safe, and potentially efficacious metabolic intervention for adults with weight-normalized anorexia nervosa. The integration of neurometabolic modulation offers a hopeful outlook for patients who have long faced limited and often unsatisfactory treatment options. By bridging nutritional science, psychiatry, and clinical care, this innovative approach could spearhead a new era of metabolic psychiatry, offering tangible recovery pathways for devastating psychiatric conditions traditionally governed by psychological and behavioral strategies alone.
The trial’s promising results compel attention from clinicians, researchers, and patient advocacy groups to consider metabolic interventions as an indispensable component of comprehensive eating disorder treatment. As ongoing research continues to elucidate the interplay between brain metabolism and psychiatric symptoms, ketogenic therapy may emerge not only as a therapeutic tool but also as a catalyst for a deeper understanding of the biological foundations of mental illness. The implications for public health, patient quality of life, and clinical practice standards hold immense transformative potential that warrants urgent exploration and multidisciplinary collaboration.
For those interested in the pioneering work and participation in the continuation of this vital research, further information can be accessed via the official clinical trial registry at ClinicalTrials.gov under the identifier NCT06000774. This marks a critical juncture in eating disorder therapeutics where metabolic precision medicine meets clinical psychiatry, illuminating new pathways toward recovery and resilience in a population desperately in need of innovation and hope.
Subject of Research: People
Article Title: Symptom impact and safety of ketogenic therapy in adults with anorexia nervosa: a feasibility trial
News Publication Date: 3-Jun-2026
Web References:
- Communications Medicine Article DOI: 10.1038/s43856-026-01644-0
- Clinical trial registry: NCT06000774
References:
- Eating disorder mortality statistics: JAMA Psychiatry
- Eating disorder prevalence in the U.S.: ANAD Eating Disorder Statistics
- Prior neurometabolic research: Nature Article on Neurometabolic Dysfunction
Image Credits: Baszucki Group
Keywords: Mental health, Eating disorders, Ketogenic therapy, Anorexia nervosa, Neurometabolic dysfunction, Psychiatric disorders, Dietary intervention, Metabolic psychiatry, Depression, Clinical trial
